Avertix

Avertix develops an implantable heart attack warning system designed to alert patients to seek medical attention for Acute Coronary Syndrome (ACS), including silent heart attacks that occur without typical symptoms. The company's flagship Guardian System is an implantable, patient-alerting device that continuously monitors cardiac signals and provides early warning of potentially life-threatening cardiac events. Founded in 2001 and headquartered in Eatontown, United States, Avertix has raised approximately $22.4M in Series B funding from investors including HHS. The company employs 34 people and addresses the critical gap in early detection of acute coronary events, particularly for high-risk patients who have previously experienced cardiac incidents. The Guardian System represents a novel approach to preventive cardiac care through continuous implantable monitoring and real-time patient alerts.